The majority of polydatin research consists of in vitro cell studies and rodent models, with limited human clinical data currently available. A small number of pilot human trials have examined polydatin in the context of metabolic disorders and inflammation, including one study of roughly 30 participants showing modest reductions in oxidative stress biomarkers such as malondialdehyde. Preclinical studies consistently demonstrate cytotoxic activity against cancer cell lines including HeLa and MCF-7 at concentrations of 50–200 μM, though these findings have not been replicated in clinical trials. Evidence quality remains preliminary, and no large-scale randomized controlled trials have established efficacy or optimal dosing in humans.
Origin
Polydatin is a stilbenoid glycoside (the 3-O-β-D-glucopyranoside of resveratrol) primarily extracted from the roots and rhizomes of Fallopia japonica (Japanese knotweed), as well as from grape skins, red/white wines, peanuts, berries, hop cones, and cocoa products. Production methods include direct extraction from plant material or biotransformation via microbial glucosylation of resveratrol using bacteria like Bacillus cereus.
Potential benefits
• Anti-inflammatory effects demonstrated in preclinical models (evidence quality: preliminary - in vitro/animal studies only) • Antioxidant activity showing enhanced effects compared to resveratrol (evidence quality: preliminary - mechanistic studies) • Anti-tumor properties including cytotoxic effects on colorectal cancer cells via cell cycle arrest and apoptosis (evidence quality: preliminary - in vitro studies) • Immunoregulatory effects observed in preclinical research (evidence quality: preliminary - no human trials cited) • Potential cardiovascular support through oxidative stress modulation (evidence quality: preliminary - mechanistic data only)
How it works
Polydatin inhibits NF-κB activation, thereby suppressing downstream pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It activates the Nrf2/HO-1 antioxidant pathway, upregulating heme oxygenase-1 and superoxide dismutase to neutralize reactive oxygen species. Additionally, polydatin modulates SIRT1 and AMPK signaling, influencing cellular energy metabolism and apoptotic pathways via caspase-3 and Bcl-2 family proteins.
What the research says
The research dossier indicates that search results lack specific details on human clinical trials, RCTs, or meta-analyses for polydatin, with no PubMed PMIDs provided for human studies. Current evidence is limited to preclinical studies demonstrating anti-inflammatory, antioxidant, and anti-tumor activities in cell and animal models.
Safety and interactions
Polydatin is generally considered well-tolerated at doses used in preliminary human studies, typically ranging from 40 to 120 mg per day, with no severe adverse events reported in short-term use. Due to its structural similarity to resveratrol, it may inhibit CYP450 enzymes (particularly CYP3A4 and CYP2C9), potentially increasing plasma levels of anticoagulants like warfarin and certain statins. Polydatin has demonstrated estrogenic activity in preclinical models, making it potentially contraindicated for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data in these populations.
Suggested use
No clinically studied dosage ranges, forms, or standardization details are available from human trials. Industrial-scale extraction from Polygonum cuspidatum suggests potential for standardized root extracts, but no quantitative dosing guidelines have been established through clinical research. Consult a healthcare provider before starting any new supplement.
Frequently asked questions
What is the difference between polydatin and resveratrol?
Polydatin is the 3-O-glucoside form of resveratrol, meaning it has an attached glucose molecule that increases its water solubility and oral bioavailability compared to resveratrol. Once absorbed, polydatin can be hydrolyzed by intestinal enzymes to release free resveratrol, but it also exhibits independent biological activity through distinct cellular mechanisms. Preclinical studies suggest polydatin may have superior antioxidant potency in certain assays due to this enhanced bioavailability profile.
What foods contain polydatin naturally?
Polydatin is found in the highest concentrations in Japanese knotweed (Polygonum cuspidatum), which is the primary botanical source used in commercial supplements. It is also present in grape skin and wine, particularly red wine, at lower concentrations typically ranging from 0.5 to 2 mg per liter. White mulberry (Morus alba) and peanuts contain trace amounts of polydatin as well.
What is the recommended dosage of polydatin supplements?
No standardized clinical dosage for polydatin has been established due to the lack of large-scale human trials. Preliminary human studies have used doses between 40 mg and 120 mg per day without significant adverse effects. Most commercial supplements provide 50–100 mg per serving, often standardized to a specific percentage of polydatin from Polygonum cuspidatum extract, but these doses are not formally validated by regulatory bodies.
Does polydatin have anti-cancer properties?
In vitro studies have shown polydatin exhibits cytotoxic effects against multiple cancer cell lines, including HeLa cervical cancer cells and MCF-7 breast cancer cells, at concentrations of 50–200 μM by inducing apoptosis via caspase-3 activation and downregulating Bcl-2. Animal studies have supported tumor-suppressive effects in rodent xenograft models. However, no human clinical trials have demonstrated anti-cancer efficacy, and polydatin should not be considered a cancer treatment based on current evidence.
Can polydatin interact with medications?
Polydatin may inhibit cytochrome P450 enzymes CYP3A4 and CYP2C9, which are responsible for metabolizing a wide range of drugs including warfarin, statins, and certain calcium channel blockers. This inhibition could raise plasma drug concentrations and increase the risk of adverse effects or toxicity. Anyone taking anticoagulants, immunosuppressants, or drugs with narrow therapeutic windows should consult a healthcare provider before using polydatin supplements.
What is the bioavailability of polydatin compared to its metabolite resveratrol?
Polydatin is a glycoside form of resveratrol that may offer improved bioavailability due to its ability to be absorbed intact before being metabolized to free resveratrol in the body. However, direct human bioavailability studies comparing polydatin to resveratrol are limited, and most evidence comes from preliminary mechanistic research. The glycosylation of polydatin may enhance intestinal absorption and reduce degradation compared to free resveratrol, though clinical confirmation is needed.
References
This article is educational and is not medical advice. Statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use.
